A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2017
At a glance
- Drugs ADX 102 (Primary)
- Indications Anterior uveitis
- Focus Therapeutic Use
- Sponsors Aldeyra Therapeutics
- 27 Apr 2017 According to an Aldeyra Therapeutics media release, results from this study are expected in the second half of 2018.
- 27 Apr 2017 According to an Aldeyra Therapeutics media release, first patient has been enrolled in the study.
- 27 Apr 2017 Status changed from planning to recruiting, according to an Aldeyra Therapeutics media release.